Management of paediatric GERD

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 3, 2014, Pages 147-157

  Vandenplas, Yvan ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR; REDUCING AGENT; ANTACID AGENT; BETHANECHOL; DOMPERIDONE; LANSOPRAZOLE; METOCLOPRAMIDE; PANTOPRAZOLE;

BODY POSITION; CHILD; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOSCOPIC SURGERY; GASTROESOPHAGEAL REFLUX; HUMAN; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REASSURANCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH SURGERY; ANTIREFLUX OPERATION; CHILD CARE; CONSERVATIVE TREATMENT; DIET THERAPY; DRUG RESPONSE; DRUG SAFETY; LAPAROSCOPIC SURGERY; MANAGED CARE; PATHOPHYSIOLOGY; PATIENT POSITIONING; TREATMENT DURATION; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; DIET; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE MANAGEMENT; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; PRESSURE; PROTON PUMP INHIBITORS;

EID: 84896035340     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.199     Document Type: Review

References (100)

1. Nelson, S. P. et al. Pediatric GERD and acid-related conditions (ARC): trends in incidence of diagnosis and acid suppression therapy. J. Med. Eco. 12, 348-355 (2009).
2. Sherman, P. M. et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am. J. Gastroenterol. 104, 1278-1295 (2009).
3. Czinn, S. J. & Blanchard, S. Gastroesophageal reflux disease in neonates and infants: when and how to treat. Paediatr. Drugs 15, 19-27 (2013).
4. Papadopoulou, A. et al. Management guidelines of eosinophilic esophagitis in childhood: A position paper of the Eosinophilic Esophagitis Working Group and the Gastroenterology Committee of ESPGHAN. J. Pediatr. Gastroenterol. Nutr. http:/dx.doi/org/10.1097/MPG.0b013e3182a80be1.
5. Vandenplas, Y. et al. Gastrointestinal manifestations of cow's milk protein allergy and gastrointestinal motility. Acta Paediatr. 101, 1105-1109 (2012).
6. Omari, T. Gastro-oesophageal reflux disease in infants and children: new insights, developments and old chestnuts. J. Pediatr. Gastroenterol. Nutr. 41 (Suppl. 1), S21-S23 (2005).
7. van Wijk, M. P. et al. Distension of the esophagogastric junction augments triggering of transient lower esophageal sphincter relaxation. Am. J. Physiol. Gastrointest Liver Physiol. 301, G713-G718 (2011).
8. van Wijk, M. P., Benninga, M. A., Davidson, G. P., Haslam, R. & Omari, T. I. Small volumes of feed can trigger transient lower esophageal sphincter relaxation and gastroesophageal reflux in the right lateral position in infants. J. Pediatr. 156, 744-748 (2010).
9. Hegar, B. et al. Natural evolution of regurgitation in healthy infants. Acta Paediatr. 98, 1189-1193 (2009).
10. Nelson, S. P., Chen, E. H. & Syniar, G. M. One year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatrics 102, e67 (1998).
11. Argon, M. et al. Relationship between gastric emptying and gastroesophageal reflux in infants and children. Clin. Nucl. Med. 31, 262-265 (2006).
12. Beaumont, H., Bennink, R. J., de Jong, J. & Boeckxstaens, G. E. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 59, 441-451 (2010).
13. Kahrilas, P. J. et al. The acid pocket: a target for treatment in reflux disease? Am. J. Gastroenterol. 108, 1058-1064 (2013).
14. Martin, A. J. et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 109, 1061-1067 (2002).
15. Orenstein, S. R., Shalaby, T. M., Kelsey, S. F. & Frankel, E. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am. J. Gastroenterol. 101, 628-640 (2006).
16. Vandenplas, Y. et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr. 49, 498-547 (2009).
17. Vandenplas, Y. et al. Practical algorithms for managing common gastrointestinal symptoms in infants. Nutrition 29, 184-194 (2013).
18. Lightdale, J. R., Gremse D. A. & Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics 131, e1684-e1695 (2013).
19. Vandenplas, Y., Leluyer, B., Cazaubiel, M., Housez, B. A. & Bocquet, A. Double-blind comparative trial with two antiregurgitation formulae. J. Pediatr. Gastroenterol. Nutr. 57, 389-393.
20. Horvath, A., Dziechciarz, P. & Szajewska, H. The effect of thickened-feed interventions on gastroesophageal reflux in infants: systematic review and meta-analysis of randomized, controlled trials. Pediatrics 122, e1268-e1277 (2008).
21. Vandenplas, Y. Thickened infant formula does what it has to do: decrease regurgitation. Pediatrics 123, e549-e550 (2009).
22. Hegar, B., Rantos, R., Firmansyah, A., De Schepper, J. & Vandenplas, Y. Natural evolution of infantile regurgitation versus the efficacy of thickened formula. J. Pediatr. Gastroenterol. Nutr. 47, 26-30 (2008).
23. Martigne, L. et al. Prevalence and management of gastroesophageal reflux disease in children and adolescents: a nationwide cross-sectional observational study. Eur. J. Pediatr. 171, 1767-1773 (2012).
24. Bosscher, D., Van Caillie-Bertrand, M. & Deelstra, H. Do thickening properties of locust bean gum affect the amount of calcium, iron and zinc available for absorption from infant formula? In vitro studies. Int. J. Food Sci. Nutr. 54, 261-268 (2003).
25. Levtchenko, E., Hauser, B. & Vandenplas, Y. Nutritional value of an "anti-regurgitation" formula. Acta Gastroenterol. Belg. 61, 285-287 (1998).
26. Borrelli, O. et al. Cow's milk challenge increases weakly acidic reflux in children with cow's milk allergy and gastroesophageal reflux disease. J. Pediatr. 161, 476-481.e1 (2012).
27. Shergill-Bonner, R. Infantile colic: practicalities of management, including dietary aspects. J. Fam. Health Care 20, 206-209 (2010).
28. Vandenplas, Y., Hauser, B. & Devreker, T. A pilot trial on acceptability, tolerance, and efficacy of a thickened extensive casein hydrolysate (Allernova AR®) [abstract 1066]. Pediatr. Res. 68, 529 (2010).
29. Vandenplas, Y. et al. A preliminary report on the efficacy of the "Multicare AR-Bed(R.)" in 3 weeks-3 month old infants on regurgitation, associated symptoms and acid reflux. Arch. Dis. Child. 95, 26-30 (2010).
30. van Wijk, M. P et al. Effect of body position changes on postprandial gastroesophageal reflux and gastric emptying in the healthy premature neonate. J. Pediatr. 151, 585-590 (2007).
31. Lewak, N. Prone sleeping is a risk for SIDS, not for suffocation. Pediatrics 130, e1389 (2012).
32. Mitchell, E. A. et al. Risk factors for sudden infant death syndrome following the prevention campaign in New Zealand: a prospective study. Pediatrics 100, 835-840 (1997).
33. Scragg, R. K. & Mitchell, E. A. Side sleeping position and bed sharing in the sudden infant death syndrome. Ann. Med. 30, 345-349 (1998).
34. Scherer, L. D., Zikmund-Fisher, B. J., Fagerlin, A. & Tarini, B. A. Influence of "GERD" label on parents' decision to medicate infants. Pediatrics 131, 839-845 (2013).
35. Maclennan, S., Augood, C., Cash-Gibson, L., Logan, S. & Gilbert, R. E. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Systematic Reviews, Issue 4. Art. No.: CD002300. doi:10.1002/14651858. CD002300.pub2.
36. Craig, W. R., Hanlon-Dearman, A., Sinclair, C., Taback, S. & Moffatt, M. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Systematic Reviews, Issue 5. Art. No.: CD003502. doi:10.1002/14651858. CD003502.pub3.
37. Tolia, V., Calhoun, J., Kuhns, L. & Kauffman, R. E. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J. Pediatr. 115, 141-145 (1989).
38. Machida, H. M., Forbes, D. A., Gall, D. G. & Scott, R. B. Metoclopramide in gastroesophageal reflux of infancy. J. Pediatr. 112, 483-487 (1988).
39. Shafrir, Y., Levy, Y., Beharab, A., Nitzam, M. & Steinherz, R. Acute dystonic reaction to bethanechol-a direct acetylcholine receptor agonist. Dev. Med. Child. Neurol. 28, 646-648 (1986).
40. Madani, S. & Tolia, V. Gynecomastia with metoclopramide use in pediatric patients. J. Clin. Gastroenterol. 24, 79-81 (1997).
41. Putnam, P. E., Orenstein, S. R., Wessel, H. B. & Stowe, R. M. Tardive dyskinesia associated with use of metoclopramide in a child. J. Pediatr. 121, 983-985 (1992).
42. Pritchard, D. S., Baber, N. & Stephenson, T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br. J. Clin. Pharmacol. 59, 725-729 (2005).
43. Nguyen, J. et al. Acute extrapyramidal manifestations caused by domperidone. Arch. Pediatr. 7, 1131-1132 (2000).
44. Vieira, M. C., Miyague, N. I., Van Steen, K., Salvatore, S. & Vandenplas, Y. Effects of domperidone on QTc interval in infants. Acta Paediatr. 101, 494-496 (2012).
45. Hegar, B., Alatas, S., Advani, N., Firmansyah, A. & Vandenplas, Y. Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study. Acta Paediatr. 98, 750-755 (2009).
46. Michaud, V. & Turgeon, J. Domperidone and sudden cardiac death: how much longer should we wait? J. Cardiovasc. Pharmacol. 61, 215-217 (2013).
47. Scott, B. Question 2. How effective is domperidone at reducing symptoms of gastro-oesophageal reflux in infants? Arch. Dis. Child. 97, 752-755 (2012)
48. Hondeghem, L. M. Domperidone: limited benefits with significant risk for sudden cardiac death. J. Cardiovasc. Pharmacol. 61, 218-225 (2013).
49. Omari, T. I. et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J. Pediatr. 149, 468-474 (2006).
50. Del Buono, R., Wenzl, T. G., Ball, G., Keady, S. & Thomson, M. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Arch. Dis. Child. 90, 460-463 (2005).
51. Donnellan, C., Preston, C., Moayyedi, P. & Sharma, N. Medical treatments for the maintenance therapy of reflux oseophagitis and endoscopic negative reflux disease. Cochrane Database Systematic Reviews, Issue 4. Art. No.: CD003245. doi:10.1002/14651858. CD003245.pub2.
52. Salvatore, S., Hauser, B., Salvatoni, A. & Vandenplas, Y. Oral ranitidine and duration of gastric pH 4.0 in infants with persisting reflux symptoms. Acta Paediatr. 95, 176-181 (2006).
53. Hemmink, G. J. et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am. J. Gastroenterol. 103, 2446-2453 (2008).
54. Turk, H., Hauser, B., Brecelj, J., Vandenplas, Y. & Orel, R. Effect of proton pump inhibition on acid, weakly acid and weakly alkaline gastro-esophageal reflux in children. World J. Pediatr. 9, 36-41 (2013).
55. Malcolm, W. F. & Cotten, C. M. Metoclopramide, H2 blockers, and proton pump inhibitors: pharmacotherapy for gastroesophageal reflux in neonates. Clin. Perinatol. 39, 99-109 (2012).
56. Chai, G. et al. Trends of outpatient prescription drug utilization in US children, 2002-2010 Pediatrics 130, 23-31 (2012).
57. Chen, I. L. et al. Proton pump inhibitor use in infants: FDA reviewer experience. J. Pediatr. Gastroenterol. Nutr. 54, 8-14 (2012).
58. Ward, R. M. & Kearns, G. L. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr. Drugs 15, 119-131 (2013).
59. Ward, R. M. et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J. Clin. Pharmacol. 51, 876-887 (2011).
60. Knebel, W. et al. Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. J. Clin. Pharmacol. 51, 333-345 (2011).
61. Tammara, B. K. et al. Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. Clin. Pharmacokinet. 50, 541-550 (2011).
62. Kierkus, J. et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Dig. Dis. Sci. 56, 425-434 (2011).
63. Ward, R. M. et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur. J. Clin. Pharmacol. 66, 555-561 (2010).
64. Springer M., Atkinson, S., North, J. & Raanan M. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. Paediatr. Drugs 10, 255-263 (2008).
65. Ponrouch, M. P. et al. Proton pump inhibitor administration via nasogastric tube in pediatric practice: comparative analysis with protocol optimization. Int. J. Pharm. 390, 160-164 (2010).
66. Hudson, B. et al. Crying and spilling-time to stop the overmedicalisation of normal infant behaviour. N. Z. Med. J. 125, 119-126 (2012).
67. Heine, R. G., Jaquiery, A., Lubitz, L. Cameron, D. J. & Catto-Smith, A. G. Role of gastro-oesophageal reflux in infant irritability. Arch. Dis. Child. 73, 121-125 (1995).
68. Orenstein, S. R., Hassall, E., Furmaga-Jablonska, W., Atkinson, S. & Raanan, M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J. Pediatr. 154, 514-520 (2009).
69. Winter, H. et al. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J. Pediatr. Gastroenterol. Nutr. 55, 14-20 (2012).
70. Malcolm, W. F. et al. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics 121, 22-27 (2008).
71. Golski, C. A. et al. Pediatric specialists' beliefs about gastroesophageal reflux disease in premature infants. Pediatrics 125, 96-104 (2010).
72. Barney, C. K. et al. Lansoprazole, ranitidine, and metoclopramide: comparison of practice patterns at 4 level III NICUs within one healthcare system. Adv. Neonatal Care 9, 129-131 (2009).
73. Giuliano, C., Wilhelm, S. M. & Kale-Pradhan, P. B. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev. Clin. Pharmacol. 5, 337-344 (2012).
74. Danziger, J. et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 83, 692-699 (2013).
75. Targownik, L. E. et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Am. J. Gastroenterol. 107, 1361-1369 (2012).
76. Untersmayr, E. et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J. 19, 656-658 (2005).
77. Untersmayr, E. & Jensen-Jarolim, E. The role of protein digestibility and antacids on food allergy outcomes. J. Allergy Clin. Immunol. 121, 1301-1308 (2008).
78. Andersen, A. B. et al. Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study. Aliment. Pharmacol. Ther. 35, 1190-1198 (2012).
79. Spechler, S. J. et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285, 2331-2338 (2001).
80. Wijnhoven, B. P., Lally, C. J., Kelly, J. J., Myers, J. C. & Watson, D. I. Use of antireflux medication after antireflux surgery. J. Gastrointest. Surg. 12, 510-517 (2008).
81. Loots, C. et al. Gastroesophageal reflux, esophageal function, gastric emptying, and the relationship to dysphagia before and after antireflux surgery in children. J. Pediatr. 162, 566-573 (2013).
82. Esposito, C. et al. Long-term outcome of laparoscopic Nissen procedure in pediatric patients with gastroesophageal reflux disease measured using the modified QPSG Roma III European Society for Pediatric Gastroenterology Hepatology and Nutrition's questionnaire. J. Laparoendosc. Adv. Surg. Tech. 22, 937-940 (2012).
83. Granero Cendón, R. et al. Evaluation of quality of life in patients operated on for gastroesophageal reflux in the pediatric age. Cir. Pediatr. 25, 82-86 (2012).
84. Mauritz, F. A. et al. The effects and efficacy of antireflux surgery in children with gastroesophageal reflux disease: a systematic review. J. Gastrointest. Surg. 15, 1872-1878 (2011).
85. Hambraeus, M., Arnbjörnsson, E. & Anderberg, M. A literature review of the outcomes after robot-assisted laparoscopic and conventional laparoscopic Nissen fundoplication for gastro-esophageal reflux disease in children. Int. J. Med. Robot. http://dx.doi.org/10.1002/rcs.1517.
86. Hill, S. J. & Wulkan, M. L. Cardiaplication as a novel antireflux procedure for infants: a proof of concept in an infant porcine model. J. Laparoendosc Adv. Surg. Tech. 23, 74-77 (2013).
87. Chen, S., Jarboe, M. D. & Teitelbaum, D. H. Effectiveness of a transluminal endoscopic fundoplication for the treatment of pediatric gastroesophageal reflux disease. Pediatr. Surg. Int. 28, 229-234 (2012).
88. Baker, R. et al. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clin. Pediatr. 49, 852-865 (2010).
89. Hill, S. J., Pandya, S., Clifton, M. S., Bhatia, A. S Wulkan, M. L. Cardiaplication: a novel surgical technique for refractory gastroesophageal reflux in the pediatric population. J. Laparoendosc Adv. Surg. Tech. 21, 873-875 (2011).
90. Davidson, G. et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J. Pediatr. 163, 692-698 (2013)
91. Higginbotham, T. W. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease. Ann. Pharmacother. 44, 572-576 (2010).
92. Lee, J. H., Kim, M. J., Lee, J. S. & Choe, Y. H. The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children. Arch. Dis. Child. 96, 9-13 (2011).
93. Terrin, G., Canani, R. B., Passariello, A., Caoci, S. & De Curtis, M. Inhibitors of gastric acid secretion drugs increase neonatal morbidity and mortality. J. Matern. Fetal Neonatal Med. 25 (Suppl. 4), 85-87 (2012).
94. Tjon, J. A., Pe, M., Soscia, J. & Mahant, S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy http://dx.doi.org/10.1002/phar.1299.
95. Tolia, V., Youssef, N. N., Gilger, M. A., Traxler, B. & Illueca, M. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatr. 10, 41 (2010).
96. Ummarino, D. et al. Impact of antisecretory treatment on respiratory symptoms of gastroesophageal reflux disease in children. Dis. Esophagus 25, 671-677 (2012).
97. van der Pol, R. J. et al. Efficacy of proton pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 127, 925-935 (2012).
98. Wheatley, E. & Kennedy, K. A. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J. Pediatr. 155, 516-521 (2009).
99. Winter, H. et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J. Pediatr. Gastroenterol. Nutr. 50, 609-618 (2010).
100. Winter, H. et al. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J. Pediatr. Gastroenterol. Nutr. 55, 14-20 (2012).